Impact of initial respiratory compliance in ventilated patients with acute respiratory distress syndrome related to COVID-19

Florent Laverdure 1*, Amélie Delaporte 1, Astrid Bouteau 1, Thibaut Genty 1, François Decailliot 2 and François Stéphan 1

Keywords: COVID-19, Acute respiratory distress syndrome, Invasive mechanical ventilation, Respiratory compliance, Prone positioning, Positive end-expiratory pressure

Dear Editor,

Coronavirus disease 2019 (COVID-19) is associated with a high fatality rate in patients requiring invasive mechanical ventilation (IMV) [1]. COVID-19-related acute respiratory distress syndrome (COVID-ARDS) might exhibit vascular insults, resulting in loss of hypoxic pulmonary vasoconstriction, and subsequent dissociation between profound hypoxemia and preserved static compliance of the respiratory system (Cst-rs) [2]. Experts recently distinguished two phenotypes of COVID-ARDS according to their Cst-rs [2]: patients were classified as groups L (low elastance or high Cst-rs) and low recruitability) and H (high elastance and high recruitability). They recommended different ventilatory approaches [3], contrary to Sepsis Surviving Campaign guidelines [4]. We describe characteristics and outcomes in patients with different initial Cst-rs, but all receiving IMV following ARDS guidelines.

We report the courses of respiratory parameters and outcomes in an observational cohort of 36 patients who developed COVID-ARDS requiring IMV from March 17 to April 18, 2020. Patients were divided into two groups (low and high Cst-rs) according to their initial Cst-rs was above or below the median value. We applied institutional ARDS procedures to all patients. Our management was based on the systematic use of neuromuscular blockers for at least 48 h, positive end-expiratory pressures (PEEP) titrated on oxygenation, and prone positioning sessions if PaO₂/FiO₂ ratio dropped below 150. Patients’ data were analyzed until patients were discharged from the intensive care unit or died. Courses of Cst-rs, PEEP, and tidal volumes were analyzed using a linear mixed model.

The median baseline Cst-rs was 36 mL/cmH₂O [interquartile range (IQR) 29–44]. Characteristics of the patients at baseline, therapeutic interventions, and outcome measures are provided in Table 1. Twenty-nine patients (80.6%) in whom PaO₂/FiO₂ ratio dropped below 150 were placed in prone position. Courses of Cst-rs, PEEP, and tidal volumes are provided in Fig. 1. Cst-rs did not vary over time in both groups and remained higher in the high Cst-rs group (mean difference 17.7 mL/cmH₂O [95% CI 11.3–24.0] compared to the low

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Tidal volumes were higher in the high Cst-rs group (mean difference 0.90 mL/kg [95% CI 0.31–1.50] compared to the low Cst-rs group, \( P = 0.005 \)). PEEP levels were not different between groups and decreased over time.

On day 28, 32 patients (88.9%) survived and 25 (69.4%) were discharged from the intensive care unit. As of May 30, 2020, weaning from mechanical ventilation was effective in 16 high Cst-rs patients (94.1%) and 13 low Cst-rs patients (68.4%) (\( P = 0.09 \)).

As previously suggested [3], some COVID-ARDS patients exhibit high initial Cst-rs. However, the median baseline Cst-rs was not different from Cst-rs observed in “typical” non-COVID-ARDS, as demonstrated in another study [5]. The high Cst-rs did not drop and remained different from the initial low Cst-rs during the first 28 days, suggesting a lack of transition from a high to a low Cst-rs phenotype in patients receiving neuromuscular blockers. We therefore hypothesize that if this transition exists, self-inflicted lung injury during spontaneous ventilation or asynchronies is one of its main determinants.

Although therapeutic management of low Cst-rs patients is not disputed [2, 6], a low-PEEP, high-FiO\(_2\), liberal tidal volume approach has been suggested for high Cst-rs patients. Using established ARDS therapies [3] with either low or high Cst-rs, the survival rate is better

### Table 1 Baseline characteristics, therapeutic interventions, and outcomes of patients, according to respiratory compliance

|                         | Overall (\( N = 36 \)) | High respiratory compliance (\( N = 17 \)) | Low respiratory compliance (\( N = 19 \)) | \( P \) value between groups |
|-------------------------|------------------------|-------------------------------------------|------------------------------------------|------------------------------|
| **Baseline characteristics** |                        |                                           |                                         |                              |
| Age, mean ± SD, years   | 53.4 ± 10.2            | 56.1 ± 7.1                                | 50.9 ± 12.1                              | 0.12                         |
| Male sex                | 30 (83.3)              | 16 (94.1)                                 | 14 (73.7)                                | 0.18                         |
| Obesity\(^b\)           | 14 (38.9)              | 3 (17.7)                                  | 11 (57.9)                                | 0.02                         |
| Diabetes mellitus       | 11 (30.6)              | 5 (29.4)                                  | 6 (31.6)                                 | 1.0                          |
| Arterial hypertension   | 16 (44.4)              | 11 (64.7)                                 | 5 (26.3)                                 | 0.19                         |
| SAPS 2 score, median [IQR] | 31 [27–36]           | 31 [29–36]                               | 29 [22–39]                               | 0.51                         |
| SOFA score, median [IQR] | 5 [4–7]              | 6 [4–7]                                   | 4 [3–6]                                  | 0.04                         |
| Tidal volume, mean ± SD, mL/kg | 6.1 ± 0.6           | 6.2 ± 0.3                                 | 6.0 ± 0.7                                | 0.02                         |
| Respiratory frequency, median [IQR], breaths/min | 25 [24–27] | 25 [24–26] | 26 [24–28] | 0.64 |
| FiO\(_2\), median [IQR], % | 65 [50–100]          | 60 [40–80]                                | 70 [60–100]                              | 0.07                         |
| PaO\(_2\)/FiO\(_2\) ratio, median [IQR] | 152 [112–240] | 209 [150–256] | 117 [83–201] | 0.02 |
| PEEP, mean ± SD, cmH\(_2\)O | 13.4 ± 3.2          | 13.4 ± 3.6                                | 13.4 ± 3.1                               | 0.92                         |
| Respiratory compliance, mean ± SD, mL/cmH\(_2\)O\(^c\) | 39.4 ± 16.9         | 51.8 ± 16.4                               | 28.3 ± 6.1                               |                              |
| **Therapeutic interventions** |                         |                                           |                                         |                              |
| Prone positioning       | 29 (80.6)              | 12 (70.6)                                 | 17 (89.5)                                | 0.22                         |
| Number of sessions, median [IQR] | 4.0 [2.0–6.0] | 4.0 [2.5–5.0] | 5.0 [1.7–6.0] | 0.91 |
| Inhaled nitric oxide    | 9 (25.0)               | 2 (11.8)                                  | 7 (36.8)                                 | 0.13                         |
| Venovenous ECMO         | 7 (19.4)               | 0 (0.0)                                   | 7 (36.8)                                 | 0.008                        |
| Vasopressors            | 31 (86.1)              | 17 (100.0)                                | 14 (73.7)                                | 0.048                        |
| Renal replacement therapy | 7 (19.4)            | 3 (17.7)                                  | 4 (21.1)                                 | 1.0                          |
| Hydroxychloroquine      | 32 (88.9)              | 16 (94.1)                                 | 16 (84.2)                                | 0.6                          |
| Steroids                | 11 (30.6)              | 5 (29.4)                                  | 6 (31.6)                                 | 1.0                          |
| **Outcomes**            |                        |                                           |                                         |                              |
| Ventilator-free days, median [IQR] | 3.0 [0.0–14.5] | 10.0 [0.0–17.2] | 0.0 [0.0–8.0] | 0.04 |
| Mortality at day 28     | 4 (11.1)               | 1 (5.9)                                   | 3 (15.8)                                 | 0.61                         |

Abbreviations: ECMO extracorporeal membrane oxygenation, FiO\(_2\) fraction of inspired oxygen, PEEP positive end-expiratory pressure

\(^a\)Unless otherwise indicated

\(^b\)Obesity is defined by a body mass index above 30 kg/m\(^2\). The formula for body mass index is weight in kilograms divided by height in meters squared

\(^c\)No statistical comparison performed
Limitations include the small number of patients and the retrospective design. While further study is needed, our findings provide arguments to treat all COVID-ARDS with established ARDS therapies, whatever the initial value of Cst-rs.
Abbreviations
ARDs: Acute respiratory distress syndrome; COVID-19: Coronavirus disease 2019; Cst-rs: Static compliance of the respiratory system; IMV: Invasive mechanical ventilation; PEEP: Positive end-expiratory pressure

Acknowledgements
We thank all clinical and nursing staff of Marie Lannelongue Hospital for their flawless commitment during this outbreak. We also thank Sebastien Morisset, MSc, for performing the statistical analysis, and Vincent Roth, MD (Easy CRF SAS®), for providing us the database.

Authors’ contributions
FL and FS have designed the work. All authors have drafted the work. All authors have made the acquisition, analysis, and interpretation of the data. All contributors read and approved the manuscript.

Funding
The present study was supported solely by institutional sources.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The entire project was approved by the Groupe Hospitalier Paris Saint Joseph Ethics Board (IRB 00012157. Project number: 20-37816004), which waived informed consent.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Paris, France. 2Pediatric Intensive Care Unit, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Paris, France.

Received: 3 June 2020 Accepted: 1 July 2020
Published online: 09 July 2020

References
1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5,700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20): https://doi.org/10.1001/jama.2020.6775.
2.Gattinoni L, Chiurmeo D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020;24:154 https://doi.org/10.1186/s13054-020-02880-z.
3. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020; https://doi.org/10.1001/jama.2020.6825.
4. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020. https://doi.org/10.1097/CCM.0000000000004363.
5. Hauidebourg A-F, Perier F, Tuffer S, de Prost N, Razzi K, Mekontso Dessap A, et al. Respiratory mechanics of COVID-19 vs. non-COVID-19 associated acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020. https://doi.org/10.1164/rccm.202004-1226LE.
6. Ziehr DR, Alladina J, Petri CR, Maley JH, Moskowitz A, Medoff BD, et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. Am J Respir Crit Care Med. 2020; https://doi.org/10.1164/rccm.202004-1163LE.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.